Cardiovascular Benefit of Merck’s Vytorin Unreliable, FDA Advisors Say

Drug Industry Daily
A A
Despite a vast, “herculean feat” to obtain clinical trial data, the effect of Merck’s lipid-lowering Vytorin on cardiovascular health was just too small — with worrying holes in data that could hinder any proof of clinical meaningfulness, FDA advisors said.

To View This Article:

Login

Subscribe To Drug Industry Daily